From Invention to iPhone App: Digital Diagnostics and Therapeutics in SUD (A) Custom Case Solution & Analysis

Evidence Brief: Digital Diagnostics and Therapeutics in SUD

1. Financial Metrics

Pricing: The initial price for a 90-day prescription of reSET was established at approximately 1,660 dollars per patient.
Development Cost: Significant capital was required to fund clinical trials necessary for the FDA de novo pathway, though specific total R and D spend for the A case period is categorized as high-millions.
Market Potential: Over 20 million Americans suffer from substance use disorder, but fewer than 10 percent receive specialty treatment.
Reimbursement Status: At the time of the case, no dedicated CPT codes existed for prescription digital therapeutics, forcing reliance on miscellaneous or pharmacy benefit claims.

2. Operational Facts

Product Duration: The therapeutic intervention is designed as a 12-week (90-day) program delivered via a mobile application.
Clinical Efficacy: Clinical trials demonstrated a 40.3 percent abstinence rate in the treatment group compared to 17.6 percent in the control group for patients with non-opioid substance use disorders.
Regulatory Milestone: reSET received FDA clearance in September 2017 as the first software-as-a-medical-device for treating SUD.
Distribution Model: The software requires a clinician-initiated prescription and a unique access code provided to the patient.

3. Stakeholder Positions

Dr. Akshat Shah: Founder focused on bridging the gap between behavioral therapy and digital accessibility.
FDA: Established the de novo pathway to regulate software that claims to treat a disease.
Payers: Expressed skepticism regarding the long-term cost-offset of digital apps compared to traditional outpatient programs.
Clinicians: Concerned about the time required to learn new digital platforms and the lack of reimbursement for monitoring patient data.

4. Information Gaps

Long-term Retention: The case lacks data on patient relapse rates 12 months post-app usage.
Sales Force Efficiency: There is no data on the cost per acquisition for a prescribing physician in the digital therapeutic space.
Payer Contracts: Specific details on which major insurers have moved from pilot programs to full coverage are absent.

Strategic Analysis

1. Core Strategic Question

How can Pear Therapeutics transform a clinically validated software product into a commercially viable medical category given the lack of established reimbursement pathways and physician adoption incentives?

2. Structural Analysis

The digital therapeutic market faces a structural barrier in the Payer-Provider-Patient triad. While the FDA has validated the clinical utility, the financial infrastructure is lagging. Specifically, the bargaining power of payers is absolute because there is no mandated coverage for software-based medicine. Furthermore, the threat of substitutes is high, not from other apps, but from the status quo of doing nothing or relying on limited in-person counseling sessions that are already integrated into insurance networks.

3. Strategic Options

Option	Rationale	Trade-offs	Requirements
Pharma Commercial Partnership	Utilize the existing sales infrastructure of a major pharmaceutical company to reach clinicians.	Loss of margin and brand control; risk of being deprioritized by the partner.	A formal agreement with a firm like Sandoz or similar.
Direct-to-Employer Model	Bypass traditional insurers by selling to self-insured employers looking to reduce disability costs.	Smaller initial scale; requires a different sales approach focused on productivity.	Data proving that SUD treatment reduces absenteeism.
Medicaid Advocacy Strategy	Focus exclusively on state Medicaid programs where SUD prevalence and costs are highest.	Subject to political shifts and lower per-unit reimbursement rates.	Lobbying efforts to create state-specific billing codes.

4. Preliminary Recommendation

The preferred path is the Pharma Commercial Partnership. The primary hurdle for Pear is not the technology but the last mile of healthcare: getting a doctor to write a script. A partnership provides the necessary boots on the ground to educate physicians without the prohibitive cost of building a 500-person internal sales team. This path prioritizes market penetration over immediate margin retention.

Implementation Roadmap

1. Critical Path

Month 1-3: Finalize commercial terms with a pharmaceutical partner to utilize their addiction-specialty sales force.
Month 3-6: Develop and deploy an EMR-integrated prescribing module to reduce clinician friction.
Month 6-12: Execute a targeted launch in five high-prevalence states to generate real-world economic evidence for payers.

2. Key Constraints

Physician Workflow: Doctors will not prescribe the app if it adds more than three minutes to their patient interaction time.
Payer Coding: The absence of a National Drug Code (NDC) equivalent for software remains the primary bottleneck for pharmacy benefit managers.

3. Risk-Adjusted Implementation Strategy

The strategy assumes that clinical validation leads to adoption. To mitigate the risk of slow physician uptake, the implementation will include a digital bridge program. This program will allow patients to start the 12-week course through a manufacturer-sponsored voucher while insurance claims are being adjudicated. This ensures the 90-day therapeutic window is not missed due to administrative delays. Contingency planning includes a shift to a direct-to-consumer wellness version if the prescription-only model fails to gain 20 percent market coverage within 24 months.

Executive Review and BLUF

1. BLUF

Pear Therapeutics must prioritize commercial infrastructure over further product development. FDA clearance is a regulatory victory but a commercial non-event without a standardized reimbursement mechanism. The current prescription-only model is high-risk because it mimics the pharmaceutical path without the benefit of established pharmacy distribution networks. The company should secure a heavy-weight commercial partner to drive clinician adoption while simultaneously lobbying for a permanent CPT code. Failure to secure predictable reimbursement within 18 months will exhaust capital reserves and relegate the technology to a niche clinical tool rather than a mass-market therapeutic.

2. Dangerous Assumption

The analysis assumes that clinicians are willing to prescribe software. In reality, the medical community often views digital tools as supplements rather than primary treatments. If physicians do not view the app as a medical necessity, the sales force will face insurmountable resistance regardless of clinical data.

3. Unaddressed Risks

Data Privacy Liability: The collection of sensitive SUD patient data via a mobile app creates a massive target for breaches, with consequences that could bankrupt the firm.
Technical Obsolescence: Rapid mobile OS updates may break app functionality, leading to treatment interruptions that negate the clinical efficacy proven in controlled trials.

4. Unconsidered Alternative

The team has not evaluated a freemium model where a basic version of the app is provided to clinics at no cost to establish the platform as the industry standard, with the prescription-strength version (reSET) sold as a premium upgrade for high-risk patients. This would build a user base faster than the current gate-kept approach.